• Users Online: 723
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
RESEARCH ARTICLE
Year : 2017  |  Volume : 6  |  Issue : 1  |  Page : 51-58

Effect of scopolamine and mecamylamine on antidepressant effect of rivastigmine in a behavioral despair test in mice


1 Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical sciences, Isfahan university of Medical Sciences, Isfahan, Iran
2 Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan university of Medical Sciences, Isfahan, Iran

Correspondence Address:
Azadeh Mesripour
Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical sciences, Isfahan university of Medical Sciences, Isfahan
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Rivastigmine can decrease the severity of depression in Alzheimer's disease patients. Apart from the monoamines hypothesis of despair, it is well known that the cholinergic system is also responsible. Thus regarding the antidepressant effect of rivastigmine, the aim was evaluating the influence of scopolamine (muscarinic cholinergic receptors antagonist) and/or mecamylamine (nicotinic cholinergic receptors antagonist) co-administration with rivastigmine on depression outcome. Depression was evaluated by the tail suspension test (TST) in male mice. Immobility time was recorded manually which represents the time that animal stops attempts for escape from the unpleasant situation. Imipramine as the reference antidepressant decreased this time by increasing the hope for escape in the animal. Rivastigmine (0.75 mg/kg,sc), scopolamine and/or mecamylamine (0.5 and 1 mg/kg, ip, respectively) were injected before the TST. Rivastigmine considerably reduced the immobility time compared with the control group which indicated its antidepressant effects. The combination treatment of rivastigmine and scopolamine also reduced the immobility time compared with control. Mecamylamine co-administration with rivastigmine increased the immobility time which indicated that it prevented the antidepressant effects of rivastigmine. Ultimately by using the drugs all together the immobility time notably decreased. Therefore our results proved that nicotine cholinergic receptorstimulation is prominent in the antidepressant effects of rivastigmine. Thus nicotine receptor direct or indirect stimulants could be considered for further researches regarding antidepressants.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed351    
    Printed43    
    Emailed0    
    PDF Downloaded69    
    Comments [Add]    

Recommend this journal